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1. Introduction 
Fungal infections have received less attention over past 
decades, however mortality and morbidity rate of opportunistic 
fungal infections is exponentially increasing and the number of 
fatal incidence due to fungi is becoming comparable with that of 
tuberculosis and malaria.
1
 Pathogenic fungi, particularly Candida 
and Aspergillus species are one of the most common diagnosed 
opportunistic infections and are the causes of significant 
mortality in immunocompromised patients.
2
 On the other side, 
less threatening fungal skin infections were in the top 10 most 
prevalent diseases worldwide in 2010, affecting 984 million 
people
3
 and posing enormous health burden globally. Given that 
the majority of infections caused by C. albicans are biofilm-
related, and that this form is usually more resistant to traditional 
antifungal treatment it adds to recurrence and chronicity of the 
disease.
4,5
  
Antifungal agents are mainly divided into four classes: 
polyenes, pyrimidines, echinocandins and azoles (Fig. 1).
6
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A series of new thiophene-based guanylhydrazones (iminoguanidines) were synthesized in high 
yields using a straightforward two-step procedure. The antifungal activity of compounds was 
evaluated against a wide range of medicaly important fungal strains including yeasts, molds, and 
dermatophytes in comparison to clinically used drug voriconazole. Cytotoxic properties of 
compounds were also determined using human lung fibroblast cell line and hemolysis assay. All 
guanylhydrazones showed significant activity against broad spectrum of clinically important 
species of Candida spp., Aspergillus fumigatus, Fusarium oxysporum, Microsporum canis and 
Trichophyton mentagrophytes, which was in some cases comparable or better than activity of 
voriconazole. More importantly, compounds 10, 11, 13, 14, 18 and 21 exhibited excellent 
activity against voriconazole-resistant C. albicans CA5 with very low minimal inhibitory 
concentration (MIC) values <2 µg mL
-1
. Derivative 14, bearing bromine on the phenyl ring, was 
the most effective compound with MICs ranging from 0.25 to 6.25 µg mL
-1
. However, bis-
guanylhydrazone 18 showed better selectivity in terms of therapeutic index values. In-vivo 
embryotoxicity on zebrafish (Danio rerio) showed improved toxicity profile of 11,14 and 18 in 
comparison to that of voriconazole. Most guanylhydrazones also inhibited C. albicans yeast to 
hyphal transition, essential for its biofilm formation, while 11 and 18 were able to disperse 
preformed Candida biofilms. All guanylhydrazones showed the equal potential to interact with 
genomic DNA of C. albicans in vitro, thus indicating a possible mechanism of their action, as 
well as possible mechanism of observed cytotoxic effects. Tested compounds did not have 
significant hemolytic effect and caused low liposome leakage, which excluded the cell 
membrane as a primary target.  On the basis of computational docking experiments using both 
human and cytochrome P450 from Candida it was concluded that the most active 
guanylhydrazones had minimal structural prerequisites to interact with the cytochrome P450 
14α-demethylase (CYP51). Promising guanylhydrazone derivatives also showed satisfactory 
pharmacokinetic profile based on molecular calculations. 
2009 Elsevier Ltd. All rights reserved. 
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polyene amphotericin B was developed in 1953, and by far is the 
most potent antifungal agent for almost all invasive fungal 
infections. It binds to ergosterol, which is the major sterol in 
fungal cell membranes, and thereby forming membrane-spanning 
channels that lead to the leakage of intracellular constituents and 
finally fungal cell death. The most frequent side effects 
associated with amphotericin B are infusional toxicity and 
nephrotoxicity. Flucytosine, pyrimidine-base antifungal was 
synthesized in 1957 as a potential antitumor drug but later on it 
was discovered that it had significant fungistatic activity. 
Flucytosine itself has no antifungal activity but it is converted to 
5-fluorouracil within fungal cell, which then inhibits DNA and 
RNA synthesis. Usually, it is used in combination therapy with 
amphotericin B. The echinocandin derivative caspofungin 
inhibits the synthesis of β-(1,3)-d-glucan, an important 
component of the fungal cell wall. The major disadvantages 
associated with caspofungin are narrow spectrum of activity 
(only active against Candida spp. and Aspergillus spp.) and poor 
oral bioavailability. Voriconazole is a member of clinically 
important triazoles that are widely used for serious invasive 
fungal infections, as well as for dermal mycoses.
7
 Voriconazole 
has fungistatic activity against Candida spp. and Fusarium spp. 
and with fungicidal activity against Aspergillus spp. The 
mechanism of action of voriconazole is inhibition of fungal 
cytochrome P450-mediated (14α-lanosterol demethylation, an 
essential step in the synthesis of ergosterol. This eventually 
causes the depletion of ergosterol and disrupts the integrity of 
fungal cell membranes, eventually leading to cell lysis.
8,9
 The 
most common side effects of voriconazole therapy include visual 
disturbances, skin rashes, elevation of hepatic enzyme levels, 
headache, and hallucinations.
10-12
 
Figure 1. Clinically used antifungals. 
The increasing number of reports of fungal infections among 
immunocompromised patients and additional problems 
associated with toxicity and resistance to standard antifungal 
drugs cause an urgent need for the development of novel safe and 
effective antifungals.
13
 Apart from lower toxicity and higher 
selectivity, panfungal (broad spectrum) activity is also very 
desirable property that novel antifungals should have. 
Compounds containing imonoguanidine moiety have been 
known for a while and explored for their wide variety of 
biological activities. Antiviral,
14-16
 antiparasitic,
17-19
 and 
antibacterial
20-23 
activities of this versatile group of compounds 
have been described. However, their antifungal potential has not 
been extensively explored.
24
 More importantly, to the best of our 
knowledge, they have not been evaluated against human fungal 
pathogens. 
In a view of the general lack of novel antifungal agents and in 
a continuation of our studies towards the discovery of 
biologically active heterocyclic molecules, herein we report the 
synthesis and structural characterization of novel 
guanylhydrazones with their subsequent in vitro biological 
evaluation for antifungal activity including activity against fungal 
biofilms, their cytotoxic properties, in-vitro DNA interaction 
ability and in-silico analysis. In-vivo embryotoxicity on zebrafish 
(Danio rerio) of the most promising derivatives has been 
determined. The druglikeness of studied compounds was also 
established using Lipinski’s “rule of five”.
25,26
 
2. Materials and methods 
2.1. Instrumentation 
Melting points were determined on a Boetius PMHK 
apparatus and were not corrected. IR spectra were recorded on a 
Thermo-Scientific Nicolet 6700 FT-IR Diamond Crystal.  NMR: 
1
H and 
13
C NMR spectra were recorded on a Bruker Ultrashield 
Advance III spectrometer (at 500 and 125 MHz, respectively) 
using tetramethylsilane (TMS) as the internal standard. The 
NMR solvents are specified individually for each compound. 
Chemical shifts are expressed in parts per million (ppm) on the 
() scale. Chemical shifts were calibrated relative to those of the 
solvents. ESI MS spectra of the synthesized compounds were 
recorded on an Agilent Technologies 6210 Time-of-Flight 
LC/MS instrument in positive ion mode using CH3CN/H2O = 
1:11:1 with 0.2 % HCOOH as the carrying solvent solution.  The 
samples were dissolved in pure acetonitrile (HPLC grade).  The 
selected values were as follows: capillary voltage = 4 kV; gas 
temperature = 350 °C; drying gas = 12.l min
-1
; nebulizer pressure 
= 45 psig; fragmentator voltage = 70 V. All yields reported refer 
to isolated yields. Compounds were analyzed for purity using: 
Agilent 1200 HPLC system equipped with Quat Pump 
(G1311B), Injector (G1329B) 1260 ALS, TCC 1260 ( G1316A) 
and Detector 1260 DAD VL+ (G1315C), and Waters 1525 HPLC 
dual pump system equipped with an Alltech Select degasser 
system, and a dual λ 2487 UV-VIS detector. All compounds were 
> 95% pure. Spectroscopic data of compounds are listed below 
(
1
H and 
13
C NMR spectra are in the Supplementary material). 
2.2. General procedure for Suzuki coupling reactions 
5-phenylthiophene-2-carbaldehyde (3)
 27
: To a dry glass flask 
purged with argon were added Pd(OAc)2 (3.4 mg, 0.015 mmol), 
PPh3 (16 mg, 0.06 mmol) and dry DME (2 mL). The resultant 
solution was stirred at room temperature for 10 min, and 5-
bromo-2-thiophenecarboxaldehyde (77 L, 0.65 mmol) and 
Na2CO3 (aq) (2 M, 0.65 mL, 1.3 mmol) were added. After 5 min 
a solution of phenylboronic acid (99 mg, 0.82 mmol) in ethanol 
(1 mL) was added and reaction mixture was purged with argon 
and refluxed for 2 h under argon. The solution was cooled to 
room temperature and filtered through a pad of Celite, washed 
with CH2Cl2 and dried with anh. Na2SO4. The organic solvent 
  
 
was removed under reduced pressure and the crude product was 
purified by dry-flash chromatography (SiO2: hexane/EtOAc = 
19:1) to afford the title compound 3 (110 mg, 90%) as an pale-
yellow amorphous powder; mp = 88-90 C. IR (ATR): 3281w, 
3099w, 1637s, 1527w, 1436s, 1388m, 1329w, 1227s, 1060m, 
993w, 905w, 814m cm
-1
. 
1
H NMR (500 MHz, CDCl3): δ 9.89 (s, 
1H), 7.74 (d, 1H, J = 3.5 Hz), 7.70-7.65 (m, 2H), 7.47-7.37 (m, 
4H) ppm. 
13
C NMR (125 MHz, CDCl3 ): δ 182.78, 154.30, 
142.48, 137.36, 133.05, 129.44, 129.20, 126.44, 124.08 ppm. 
GC/MS (m/z (%)) 187.0 ([M]
+
, 100), 115.1 (55). 
5-(4-methylphenyl)thiophene-2-carbaldehyde (4)
27
: The 
general Suzuki coupling procedure was followed. The reaction 
mixture was refluxed for 18 h. The crude product was purified by 
dry-flash chromatography (SiO2: hexane/EtOAc = 19:1) to afford 
the title compound 4 (112 mg, 85%) as an pale-yellow 
amorphous powder; mp = 88-91 
o
C. IR (ATR): 3351w, 3291w, 
3095w, 3026w, 2970w, 2921w, 2850w, 2818w, 2751w, 1657s, 
1614w, 1581m, 1535w, 1490w, 1449s, 1383m, 1333w, 1286w, 
1226s, 1141w, 1123w, 1084w, 1056m, 1038w, 957w, 901w, 
854w, 802s cm
-1
. 
1
H NMR (500 MHz, CDCl3): δ 9.88 (s, 1H), 
7,72 (d, 1H, J = 4.0 Hz), 7.57 (d, 2H, J = 8.5 Hz), 7.36 (d, 1H, J 
= 4.0 Hz), 7.24 (d, 2H, J = 8.0 Hz), 2.39 (s, 3H) ppm. 
13
C NMR 
(125 MHz, CDCl3 ): δ 182.73, 154.64, 141.98, 139.74, 137.47, 
130.30, 129.87, 126.32, 123.57, 21.32 ppm. GC/MS (m/z (%)) 
202.1 ([M]
+
, 100), 173.1 (8), 129.1 (28), 115.1 (6). 
5-(4-methoxyphenyl)thiophene-2-carbaldehyde (5)
27
: The 
general Suzuki coupling procedure was followed. The reaction 
mixture was refluxed for 2 h. The crude product was purified by 
dry-flash chromatography (SiO2: hexane/EtOAc = 1:1) to afford 
the title compound 5 (175 mg, 82%) as an pale-yellow 
amorphous powder; mp = 120-121 
o
C. IR (ATR): 3029w, 1693w, 
1644s, 1600s, 1568m, 1530m, 1507m, 1453s, 1331w, 1308w, 
1287s, 1254s, 1220s, 1178s, 1112m, 1054s, 1022s, 831s, 799s 
cm
-1
. 
1
H NMR (500 MHz, CDCl3): δ 9.86 (s, 1H), 7.70 (d, 1H, J 
= 4.0 Hz), 7.61 (d, 2H, J = 9.0 Hz), 7.29 (d, 1H, J = 4.0 Hz), 6.94 
(d, 2H, J = 9.0 Hz), 3.85 (s, 3H) ppm. 
13
C NMR (125 MHz, 
CDCl3): δ 182.64, 160.71, 154.52, 141.52, 137.65, 127.80, 
125.78, 122.98, 114.58, 55.42 ppm. GC/MS (m/z (%)) 218.0 
(100), 203.0 (38), 175.0 (12), 147.0 (14). 
5-(4-fluorophenyl)thiophene-2-carbaldehyde (6)
27
: The 
general Suzuki coupling procedure was followed. The reaction 
mixture was refluxed for 2 h. The crude product was purified by 
dry-flash chromatography (SiO2: hexane/EtOAc = 4:1) to afford 
the title compound 6 (145 mg, 72%) as an pale-brown amorphous 
powder; mp = 114-116 
o
C. IR (ATR): 3092m, 2855w, 1633s, 
1594s, 1528m, 1502m, 1441s, 1413s, 1384m, 1327m, 1306m, 
1231s, 1158s, 1100s, 1058s, 959m, 832s, 803s cm
-1
. 
1
H NMR 
(500 MHz, CDCl3): δ 9.89 (s, 1H), 7.73 (d, 1H, J = 4.0 Hz), 7.68-
7.61 (m, 2H), 7.34 (d, 1H, J = 4.0 Hz), 7.17-7.10 (m, 2H) ppm. 
13
C NMR (125 MHz, CDCl3 ): δ 182.71, 163.40 (d, J = 248.2 
Hz), 153.03, 142.53, 137.38, 129.28 (d, J = 3.5 Hz), 128.29 (d, J 
= 8.1 Hz), 124.06, 116.31 (d, J = 21.8 Hz) ppm. GC/MS (m/z 
(%)) 206.0 (100), 178.0 (10), 133.0 (80), 120.0 (10), 107.0 (10). 
5-(4-bromophenyl)thiophene-2-carbaldehyde (7) The general 
Suzuki coupling procedure was followed. The reaction mixture 
was refluxed for 18 h. The crude product was purified by dry-
flash chromatography (SiO2: hexane/EtOAc = 9:1) to afford the 
title compound 7 (125 mg, 46%) as an pale-yellow amorphous 
powder; mp = 94-97 
o
C. IR (ATR): 3309w, 3103w, 2829w, 
2802w, 2742w, 1662s, 1585m, 1530m, 1491w, 1448s, 1399m, 
1324w, 1269w, 1226s, 1117w, 1079w, 1055m, 1004w, 959w, 
823s, 804s cm
-1
. 
1
H NMR (500 MHz, CDCl3): δ 9.90 (s, 1H), 
7.73 (d, 1H, J = 4.0 Hz), 7.60-7.51 (m, 4H), 7.39 (d, 1H, J = 4.0 
Hz) ppm. 
13
C NMR (125 MHz, CD3CD): δ 182.68, 152.71, 
142.84, 137.26, 132.38, 132.01, 127.83, 124.39, 123.62 ppm. 
GC/MS (m/z (%)) 267.9 (100), 192.9 (40), 158.0 (20), 115.0 
(30). 
4-(5-formylthiophen-2-yl)benzonitrile (8)
27
: The general 
Suzuki coupling procedure was followed. The reaction mixture 
was refluxed for 18 h. The crude product was purified by dry-
flash chromatography (SiO2: hexane/EtOAc = 3:7) to afford the 
title compound 8 (131 mg, 73%) as an pale-yellow amorphous 
powder; mp = 166-176 
o
C. IR (ATR): 3304w, 3099w, 3052w, 
2857w, 2826w, 2762w, 2221s, 1692s, 1673s, 1604m, 1532w, 
1450s, 1414m, 1332w, 1285w, 1231s, 1181w, 1129w, 1065w, 
837w, 802m cm
-1
. 
1
H NMR (500 MHz, CDCl3): δ 9.94 (s, 1H), 
7.81-7.75 (m, 3H), 7.75-7.69 (m, 2H), 7.50 (d, 1H, J = 4.0 Hz) 
ppm. 
13
C NMR (125 MHz, CDCl3 ): δ 182.70, 150.98, 144.15, 
137.23, 137.02, 132.97, 126.82, 125.82, 118.26, 112,66 ppm. 
GC/MS (m/z (%)): 212.0 ([M]
+
, 100), 140.1 (45). 
5-phenylfuran-2-carbaldehyde (9)
27
: The general Suzuki 
coupling procedure was followed. The reaction mixture was 
refluxed for 2 h. The crude product was purified by dry-flash 
chromatography (SiO2: hexane/EtOAc = 9:1) to afford the title 
compound 9 (145 mg, 87%) as an yellow oil; IR (ATR): 3114w, 
2814w, 1669s, 1520m, 1474m, 1449m, 1391m, 1255m, 1028m, 
967m, 920w, 802m, 765s cm
-1
. 
1
H NMR (500 MHz, CDCl3): δ 
9.65 (s, 1H), 7.85-7.80 (m, 2H), 7.47-7.42 (m, 2H), 7.41-7.37 (m, 
1H), 7.32 (d, 1H, J = 3.5 Hz), 6.84 (d, 1H, J = 4.0 Hz) ppm. 
13
C 
NMR (125 MHz, CDCl3 ): δ 177.20, 159.40, 152.01, 129.65, 
128.92, 125.27, 123.44, 107.66 ppm. GC/MS (m/z (%)) 172.1 
([M]
+
, 100), 144.1 (15), 115.1 (100), 102.1 (5), 89.1 (20), 77,1 
(7), 63.1 (15), 51.1 (10). 
2.3. General procedure for reparation of guanylhydrazones 10-
18 and 21 
2-[(5-phenylthiophen-2-yl)methylidene]hydrazine 
carboximidamide hydrochloride (10) To a solution of aldehyde 
(65 mg, 0.35 mmol) in absolute ethanol (12 mL) was added 
aminoguanidine hydrochloride (38 mg, 0.35 mmol). The resultant 
solution was stirred at room temperature for 5 min, and solution 
of concentrated HCl in absolute EtOH (39 µL, 1:25 v/v) was 
added. The reaction mixture was heated to reflux for 18 h and 
allowed to cool to room temperature. The solvent was removed 
under reduced pressure, and the crude product was washed with 
CH2Cl2 and then crystallized from EtOH/hexane (9:1) to provide 
the title compound 10 (98 mg, 100%) as a pale-yellow solid; mp 
= 184-187 
o
C. IR (ATR): 3818w, 3418m, 3307w, 3220w, 3133s, 
3086m, 2848w, 1676m, 1643s, 1608m, 1462w, 1433w, 1253w, 
1154w, 1108w, 1068w, 1005w, 925w, 802w, 757m, 688m cm
-1
. 
1
H NMR (500 MHz, CD3OD): δ 8.26 (s, 1H), 7.72-7.67 (m, 2H), 
7.45-7.38 (m, 4H), 7.37-7.32 (m, 1H) ppm. 
13
C NMR (125 MHz, 
CDCl3 ): δ 156.97, 149.62, 144.35, 138.20, 135.09, 134.24, 
130.35, 129.79, 127.09, 125.04 ppm. (+)ESI-HRMS (m/z): [M + 
H]
+
 245.08616 (error 2.52 ppm). HPLC purity: Method A: RT 
6.274, area 99.28%; method B: RT 7.407, area 99.88%. 
2-{[5-(4-methylphenyl)thiophen-2-yl]methylidene} 
hydrazinecarboximidamide hydrochloride (11) Following the 
general procedure for guanylhydrazone formation, 11 was 
obtained as a pale-yellow solid (85 mg, 59%). Mp = 244-245 
o
C. 
IR (ATR): 3938w, 3428m, 3364m, 3320m, 3220m, 3093s, 
2979m, 2916m, 2833m, 2773m, 1672s, 1617s, 1539w, 1511w, 
1463m, 1432w, 1311w, 1239w, 1185w, 1123m, 1059w, 928m, 
819w, 795m, 712w, 662w, 581w cm
-1
.
 1
H NMR (500 MHz, 
CDCl3): δ 8.25 (s, 1H), 7.57 (d, 2H, J = 8.5 Hz), 7.39 (d, 1H, J = 
3.5 Hz), 7.35 (d, 1H, J = 4.0 Hz), 7.23 (d, 2H, J = 7,5 Hz), 2.36 
(s, 3H) ppm. 
13
C NMR (125 MHz, CDCl3 ): δ 159.94, 149.90, 
144.42, 140.08, 137.62, 134.29, 132.33, 130.93, 127.01, 124.47, 
  
 
21.29 ppm. (+)ESI-HRMS (m/z): [M + H]
+
 259.10187 (error 2.59 
ppm). HPLC purity: Method A: RT 6.377, area 97.25%; method 
B: RT 7.543, area 99.87%. 
2-{[5-(4-methoxyphenyl)thiophen-2-yl]methylidene} 
hydrazinecarboximidamide hydrochloride (12) Following the 
general procedure for guanylhydrazone formation, 12 was 
obtained as a pale-yellow solid (140 mg, 72%). Mp = 260-264 
o
C. IR (ATR): 3392s, 3312m, 3285m, 3222m, 3136s, 3130s, 
3000m, 2970m, 2939m, 2916m, 2848m, 1668s, 1639s, 1603s, 
1563m, 1541w, 1507m, 1465m, 1431m, 1351m, 1289m, 
1250s,1180m, 1158m, 1119w, 1025m, 922w, 829w, 796m, 629w 
cm
-1
. 
1
H NMR (500 MHz, d-DMSO): δ 8.34 (s, 1H), 7.76-7.55 
(m, 6H), 7.50 (d, 1H, J = 4.0 Hz), 7.43 (d, 1H, J = 4.0 Hz), 7.06-
6.97 (m, 2H), 3.80 (s, 3H) ppm. 
13
C NMR (125 MHz, d-DMSO): 
δ 159.99, 155.10, 147.14, 142.88, 135.87, 133.72, 127.46, 
126.10, 123.49, 115.11, 55.70 ppm. (+)ESI-HRMS (m/z): [M + 
H]
+
 275.09530 (error -2.95 ppm). HPLC purity: Method A: RT 
6.302, area 99.10%; method B: RT 7.392, area 99.91%. 
2-{[5-(4-fluorophenyl)thiophen-2-yl]methylidene} 
hydrazinecarboximidamide hydrochloride (13) Following the 
general procedure for guanylhydrazone formation, 13 was 
obtained as a pale-yellow solid (145 mg, 100%). Mp = 195-200 
o
C. IR (ATR): 3387s, 3278s, 3221s, 3167s, 2989m, 2855m, 
2362w, 1690s, 1619s, 1538m, 1505s, 1463w, 1434w, 1350w, 
1317w, 1230m, 1154m, 1103m, 1058m, 1009m, 916m, 830m, 
791m, 658m, 578m cm
-1
. NMR (500 MHz, CD3OD): δ 8.26 (s, 
1H), 7.75-7.69 (m, 2H), 7.41 (d, 1H, J = 4.0 Hz), 7.37 (d, 1H, J = 
4.0 Hz), 7.20-7.13 (m, 2H) ppm. 
13
C NMR (125 MHz, CDCl3 ): δ 
164.45 (d, J = 246.4 Hz), 156.98, 148.35, 144.27, 138.30, 134.26, 
131.60 (d, J = 2.6 Hz), 129.12 (d, J = 8.1 Hz), 125.17, 117.18 (d, 
J = 21.8 Hz) ppm. (+)ESI-HRMS (m/z): [M + H]
+
 263.07710 
(error 3.72 ppm). HPLC purity: Method A: RT 6.293, area 
98.89%; method B: RT 7.413, area 99.59%. 
2-{[5-(4-bromophenyl)thiophen-2-yl]methylidene} 
hydrazinecarboximidamide hydrochloride (14) Following the 
general procedure for guanylhydrazone formation, 14 was 
obtained as a pale-yellow solid (72 mg, 99%). Mp = 236-240 
o
C. 
IR (ATR): 3466s, 3423m, 3277s, 3139s, 2862m, 1678s, 1611s, 
1526m, 1491w, 1463w, 1440w, 1398w, 1347w, 1314w, 1243w, 
1153w, 1111w, 1079w, 1007w, 954w, 928w, 826w, 803m cm
-1
.
 
1
H NMR (500 MHz, CD3CD): δ 8.27 (s, 1H), 7.63-7.54 (m, 4H), 
7.44-7.39 (m, 2H) ppm. 
13
C NMR (125 MHz, CD3CD): δ 156.93, 
147.93, 144.14, 138.73, 134.23, 134.18, 133.44, 128.70, 125.62, 
123.43 ppm. (+)ESI-HRMS (m/z): [M + H]
+
 322.99565 (error -
1.27 ppm). HPLC purity: Method A: RT 6.406, area 95.31%; 
method B: RT 7.581, area 96.53%. 
2-{[5-(4-cyanophenyl)thiophen-2-yl]methylidene} 
hydrazinecarboximidamide hydrochloride (15) Following the 
general procedure for guanylhydrazone formation, 15 was 
obtained as a pale-yellow solid (68 mg, 65%). Mp = 190-195 
o
C. 
IR (ATR): 3936w, 3313s, 3182s, 2364w, 2233m, 1679s, 1637s, 
1599s, 1504m, 1466m, 1412w, 1318m, 1271w, 1247m, 1177m, 
1154m, 1013w, 832w, 800w cm
-1
. 
1
H NMR (500 MHz, CD3OD): 
δ 8.29 (s, 1H), 7.88-7.84 (m, 2H), 7.79-7.74 (m, 2H), 7.59 (d, 1H, 
J = 4.0 Hz), 7.47 (d, 1H, J = 4.0 Hz) ppm. 
13
C NMR (125 MHz, 
CDCl3 ): δ 157.00, 146.65, 143.86, 140.43, 139.42, 134.21, 
134.18, 127.59, 127.35, 119.64, 112.66 ppm. (+)ESI-HRMS 
(m/z): [M + H]
+
 270.08137 (error 2.12 ppm). HPLC purity: 
Method A: RT 6.216, area 98.83%; method B: RT 7.217, area 
98.44%. 
2-[(5-phenylfuran-2-yl)methylidene]hydrazine 
carboximidamide hydrochloride (16) Following the general 
procedure for guanylhydrazone formation, 16 was obtained as a 
yellowish solid (180 mg, 100%). Mp = 66-69 
o
C. IR (ATR): 
3901w, 3882w, 3621w, 3361s, 3148s, 2962s, 2861s, 2786m, 
1676s, 1633s, 1545m, 1479m, 1448m, 1336w, 1278w, 1220w, 
1147m, 1074w, 1624w, 975w, 924w, 793w, 754m, 689w, 665w, 
638w cm
-1
. 
1
H NMR (500 MHz, CD3CD): δ 8.04 (s, 1H), 7.84-
7.78 (m, 2H), 7.43-7.40 (m, 2H), 7.37-7.31 (m, 1H), 7.03 (d, 1H, 
J = 3.5 Hz), 6.94 (d, 1H, J = 3.5 Hz) ppm. 
13
C NMR (125 MHz, 
CD3CD): δ 158.12, 157.07, 149.62, 138.83, 131.26, 130.12, 
129.78, 125.61, 118,.44, 108.85 ppm. (+)ESI-HRMS (m/z): [M + 
H]
+
 229.10821 (error -0.76 ppm). HPLC purity: Method A: RT 
6.238, area 99.40%; method B: RT 7.318, area 98.69%. 
5-(pyridin-4-yl)thiophene-2-carbaldehyde
27
 The general 
Suzuki coupling procedure was followed. The reaction mixture 
was refluxed for 18 h. The crude product was purified by dry-
flash chromatography (SiO2: hexane/EtOAc = 1:1) to afford 5-
(pyridin-4-yl)thiophene-2-carbaldehyde (125 mg, 50%) as an 
pale-brown amorphous powder; mp = 107-110 
o
C. IR (ATR): 
3445s, 2361m, 1646s, 1543m, 1447m, 1415m, 1228m, 805m, 
754w, 704m cm
-1
. 
1
H NMR (500 MHz, CDCl3): δ 9.95 (s, 1H), 
8.68 (d, 2H, J = 6.0 Hz), 7.80 (d, 1H, J = 4.0 Hz), 7.58 (d, 1H, J 
= 4.0 Hz), 7.54 (d, 2H, J = 6.0 Hz) ppm. 
13
C NMR (125 MHz, 
CDCl3): δ 182.73, 150.74, 150.14, 144.22, 140.03, 136.86, 
126.01, 120.23 ppm. (+)ESI-HRMS (m/z): [M + H]
+
 190.03231 
(error, +1.04 ppm). 
2-{[5-(pyridin-4-yl)thiophen-2-yl]methylidene}hydrazine 
carboximidamide dihydrochloride (17) Following the general 
procedure for guanylhydrazone formation, 17 was obtained as a 
pale-yellow solid (27 mg, 32%). Mp = 272-276 
o
C. IR (ATR): 
3311s, 3090s, 2992s, 2846s, 1678m, 1631s, 1535m, 1560s, 
1462w, 1376w, 1326m, 1241w, 1202w, 1145w, 1698w, 1004w, 
799w, 626w, 581w, 551w cm
-1
. 
1
H NMR (500 MHz, D2O): δ 
8.59-8.55 (m, 2H), 8.11-8.09 (m, 1H), 8.09-8.07 (m, 2H), 7.82 (d, 
1H, J = 4.5 Hz), 7.39 (d, 1H, J = 4.0 Hz) ppm. 
13
C NMR (125 
MHz, D2O): δ 154.66, 149.52, 143.66, 141.73, 141.26, 139.39, 
133.22, 131.54, 122.06 ppm. (+)ESI-HRMS (m/z): [M + 2H]
2+
 
123.54429 (error 2.09 ppm). HPLC purity: Method A: RT 6.184, 
area 99.51%; method B: RT 6.273, area 96.37%. 
5-(4-formylphenyl)thiophene-2-carbaldehyde To a dry glass 
flask purged with argon were added Pd(OAc)2 (2.9 mg, 0.013 
mmol), PPh3 (14 mg, 0.050 mmol) and dry DME (2 mL). The 
resultant solution was stirred at room temperature for 10 min, and 
5-bromo-2-thiophenecarboxaldehyde (30 µL, 0.26 mmol) and 
Na2CO3 (aq) (2 M, 0.3 mL, 0.6 mmol) were added. After 5 min a 
4-formylphenylboronic acid (49 mg, 0.33 mmol) was added and 
reaction mixture was purged with argon and refluxed for 3 h 
under argon. The solution was cooled to room temperature and 
filtered through a pad of Celite, washed with CH2Cl2 and dried 
with anh. Na2SO4. The organic solvent was removed under 
reduced pressure and the crude product was purified by dry-flash 
chromatography (SiO2: hexane/EtOAc = 7:3) to afford 5-(4-
formylphenyl)thiophene-2-carbaldehyde (54 mg, 96%) as an 
pale-yellow amorphous powder; mp = 130-132 
o
C. IR (ATR): 
3078w, 3047w, 2844w, 2757w, 1693s, 1658s, 1601s, 1566m, 
1506w, 1447s, 1396m, 1318w, 1291w, 1224s, 1183m, 1059w, 
961w, 840m, 806m cm
 -1
. 
1
H NMR (500 MHz, CDCl3): δ 10.06 
(s, 1H), 9.95 (s, 1H), 7.99-7.94 (m, 2H), 7.88-7.83 (m, 2H), 7.80 
(d, 1H, J = 4.0 Hz), 7.55 (d, 1H, J =4.0 Hz) ppm. 
13
C NMR (125 
MHz, CDCl3): δ 191.20, 182.75, 151.85, 143.95, 138.52, 137.08, 
136.48, 130.52, 126.84, 125.72 ppm. GC/MS (m/z (%)): 214.9 
([M]
+
, 100). 
2-[(5-{4-[(2-carbamimidoylhydrazinylidene)methyl] 
phenyl}thiophen-2-yl)methylidene]hydrazinecarboximidamide 
dihydrochloride (18) Following the general procedure for 
guanylhydrazone formation, 18 was obtained as a pale-yellow 
  
 
solid (37 mg, 100%). Mp = 248-250 
o
C. IR (ATR): 3352s, 3275s, 
3153s, 2872m, 1668s, 1612s, 1536m, 1437m, 1350w, 1237m, 
1181w, 1141m, 1011w, 829w cm
 -1
.
 1
H NMR (500 MHz, 
DO3OD): δ 8.30 (s, 1H), 8.15 (s, 1H), 7.86 (d, 2H, J = 8.0 Hz), 
7.78 (d, 2H, J = 8.0 Hz), 7.52 (d, 1H, J = 4.0 Hz), 7.45 (d, 1H, J 
= 4.0 Hz) ppm.
 13
C NMR (125 MHz, DO3OD): δ 157.26, 156.96, 
148.75, 148.28, 144.14, 139.14, 137.25, 134.81, 134.29, 129.67, 
127.32, 126.04 ppm. (+) ESI-HRMS (m/z): [M + H]
+
 329.12823 
(error: -2,77 ppm). HPLC purity: Method C: RT 6.322, area 
99.52%; method D: RT 2.543, area 96.86%. 
4,4'-thiene-2,5-diyldibenzaldehyde (20)
28
: A reaction tube 
containing a stirrer bar was evacuated and backfilled with argon. 
The tube was then charged with Pd(OAc)2 (16 mg, 0.070 mmol), 
PPh3 (73 mg, 0.28 mmol) and dry DME (7 mL) under argon. The 
resultant solution was stirred at room temperature for 10 min, and 
2,5-dibromothiophene (150 mg, 0.620 mmol) and Na2CO3 (aq) (2 
M, 1.2 mL, 2.4 mmol) were added. After 5 min, 4-
cyanophenylboronic acid (225 mg, 1.54 mmol) was added, the 
tube was returned under argon and capped. The reaction mixture 
was heated with stirring for 2 h at 80 °C in a MW reactor. The 
solvent was then removed under reduced pressure, and the 
reaction mixture was suspended in CH2Cl2, transferred to a 
separation funnel, and washed well with saturated Na2CO3 
solution (2×25 mL) containing 5 mL NH3. The organic layer was 
collected, dried with anh. Na2SO4, and the solvent was removed 
under reduced pressure. The crude product was purified by dry-
flash chromatography (SiO2: CH2Cl2) to afford the 4,4'-thiene-
2,5-diyldibenzonitrile (160 mg, 90%) as an pale-yellow 
amorphous powder; mp = 282-284 
o
C. IR (KBr): 3432m, 2222s, 
1599s, 1491w, 1410w, 1278w, 1176w, 838m cm
 -1
. 
1
H NMR 
(500 MHz, DMSO): δ 7.97-7.87 (m, 8H), 7.84 (s, 2H) ppm. 
To a stirred suspension of di-nitrile (20 mg, 0.070 mmol) in 
PhMe (2.5 mL) was added DIBAH (0.45 mL, 1 M in toluene) at 
0 
o
C. After stirring at 0 
o
C under Ar atmosphere for 1 h the 
reaction was quenched with 5% H2SO4 (0.60 mL), and stirring 
was continued for 1 h at r.t. The reaction mixture was transferred 
into a separation funnel as an emulsion in EtOAc (50 mL). The 
organic layer was separated, and the aqueous layer was 
additionally extracted with CH2Cl2 (3×25 mL). The combined 
organic layers were washed with brine (15 mL) and dried over 
anh. Na2SO4. The organic solvent was removed under reduced 
pressure and the crude product 20 (20 mg, 98%) was obtained as 
a pale-yellow solid and was used for the next reactions without 
further purification. Mp = 149-151 
o
C. IR (ATR): 3349w, 3198w, 
3069m, 2923m, 2854m, 2764w, 1694s, 1599s, 1568m, 1498w, 
1451w, 1423w, 1397w, 1346w, 1310w, 1280m, 1216m, 1167m, 
1116w, 838m cm
 -1
.
 1
H NMR (500 MHz, CDCl3): δ 10.03 (s, 2H), 
7.93 (d, 4H, J = 8.5 Hz), 7.80 (d, 4H, J = 8.5 Hz), 7.50 (s, 2H) 
ppm. 
(2,2'-{thiene-2,5-diylbis[benzene-4,1-diylmethylylidene]} 
dihydrazinecarboximidamide dihydrochloride (21) Following 
the general procedure for guanylhydrazone formation, 21 was 
obtained as a yellow solid (20 mg, 48%). Mp = 266 
o
C. IR 
(ATR): 3362m, 3332m, 3160m, 2917m, 2850m, 1737m, 1673s, 
1619s, 1539m, 1511m, 1456w, 1148w cm
 -1
. 
1
H NMR (500 MHz, 
DO3OD): δ 8.12 (s, 2H), 7.88-7.84 (m, 4H), 7.80-7.76 (m, 4H), 
7.54 (s, 2H) ppm.
 13
C NMR (125 MHz, DMSO): δ 155.39, 
146.25, 142.60, 135.11, 132.82, 128.44, 126.26, 125.36 ppm. (+) 
ESI-HRMS (m/z): [M + H]
+
 405.16006 (error: -0,94ppm). HPLC 
purity: Method C: RT 6.342, area 99.06%; method D: RT 2.761, 
area 95.73%. 
2.4. Broth dilution method for antifungal susceptibility testing 
The minimum inhibitory concentration (MIC) of 
guanylhydrazones to six human clinical fungal strains was 
determined using a reference method for testing antimicrobial 
agents for yeasts and moulds in a 96-well microtitre plate assay 
(EUCAST 2012; EUCAST 2014).
29,30
  All tested compounds 
were initially dissolved in DMSO in stock concentration of 50 
mg mL
-1
. Further dilutions were made in RPMI 1640 medium 
(Roswell Park Memorial Institute 1640) with 2% (w/v) glucose 
in the concentration range of 250-0.02 µg mL
-1
. Additionally, 
MIC of commercial antifungal voriconazole was determined for 
each isolate (concentration range 16-0.001 µg mL
-1
; Sigma 
Aldrich, Munich, Germany). Time-kill dependence was 
monitored spectrophotometrically at 600 nm over 12 h period at 
37 °C for selected guanylhydrazones (11, 14 and 18) and 
voriconazole using sub-MIC concentrations (70% of MIC value 
determined for the planktonic growth) on Tekan Infinite 200 Pro 
multiplate reader (Tecan Group Ltd., Männedorf, Switzerland).  
Pathogenic strains and preparation of inocula: Human 
clinical fungal strains were obtained from collection of National 
Reference Medical Mycology Laboratory (Institute of 
Microbiology and Immunology, Faculty of Medicine, University 
of Belgrade, Belgrade) and included: yeasts isolated from blood 
(Candida albicans CA5 and C. parapsilosis CA27); non-
dermatophyte mould isolated from upper respiratory tract 
(Fusarium oxysporum AB18); and dermatophyte moulds isolated 
from skin derivates (Trichophyton mentagrophytes DMT2 and 
Microsporum canis DMT4). The reference strains C. albicans 
ATCC10231, C. krusei ATCC34135 and Aspergillus fumigatus 
ATCC13073 were obtained from American Type Culture 
Collection (ATCC).  Stock culture of each isolate was maintained 
on Potato dextrose agar (PDA; Hi Media Laboratories Mumbai, 
India) at 4 °C. Prior to testing, working cultures were obtained by 
preculturing stock cultures onto PDA in Petri dishes and 
incubating for 7 days at 30 °C. The inocula were prepared by 
resuspending fungal conidia from PDA working cultures in 4 mL 
of sterile distilled water (for yeasts) or in 0.9% (w/v) NaCl with 
0.1% (v/v) Tween 20 (for moulds). Conidial suspensions were 
adjusted to 2-5 ×10
6
 CFU mL
-1
 by using Neubauer 
haemocytometer and diluted in RPMI 1640 medium with 2% 
glucose in a ratio of 1:10 (2-5 × 10
5
 CFU mL
-1
). 
Volume of 100 µL of prepared inocula was incubated together 
with 100 µL of different concentrations of guanylhydrazones and 
voriconazole at 37 °C (for yeasts) or at 30 °C (for moulds) and 
the growth inhibition was assessed over time (24 h for Candida 
spp.; 48 h for A. fumigatus and F. oxysporum and 96 h for M. 
canis and T. mentagrophytes).  Controls containing solvents were 
carried out in each assay. MIC was defined as the lowest 
concentration of compound at which no evident fungal growth 
was observed. The assay was repeated two times in triplicates.  
2.5. Microscopic studies 
C. albicans ATCC10231 overnight culture was diluted to 
OD600=1 and incubated with MIC of compounds 11 and 18. At 
time points 0 min and 2 h the cell viability and membrane 
integrity were assessed after staining with 1 µg mL
-1
 2-(4-
amidinophenyl)-6-indolecarbamidine dihydrochloride (DAPI, 
Sigma Aldrich), 2.5 µM propidium iodide (PI, Sigma Aldrich) 
and 50 µg mL
-1
 Concanavalin A conjugated with FITC (Sigma 
Aldrich) in PBS using fluorescence microscope (Olympus BX51, 
Applied Imaging Corp., San Jose, USA) at 40× magnification. 
2.6. Aniproliferative assay on human fibroblast cell line 
Antiproliferative activity was tested by (3-(4,5-
dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) 
  
 
assay on human lung fibroblasts (MRC5; ATCC collection). The 
cells were incubated in the media containing test compounds at 
concentrations ranging from 0.1 to 250 µg mL
-1
 and the cell 
viability was measured after 48 h. MRC5 cell line was cultured in 
RPMI-1640 medium supplemented with 100 µg mL
-1
 
streptomycin, 100 U mL
-1
 penicillin and 10% (v/v) fetal bovine 
serum (FBS) (all from Sigma, Munich, Germany). Cells were 
maintained as a monolayer (1 x 10
4 
cells per well) in RPMI-1640 
and grown in humidified atmosphere of 95% air and 5% CO2 at 
37 °C. 
The extent of MTT reduction was measured 
spectrophotometrically at 540 nm using Tekan Infinite 200 Pro 
multiplate reader (Tecan Group Ltd., Männedorf, Switzerland) 
and the cell survival was expressed as percentage of the control 
(untreated cells). The percentage viability values were plotted 
against the log of concentration and a sigmoidal dose response 
curve was calculated by non-linear regression analysis using 
Graphpad Prism software version 5.0 for Windows (Graphpad 
Software, CA, USA). Cytotoxicity is expressed as the 
concentration of the compound inhibiting growth by 50% (IC50). 
2.7. Hemolytic assay 
Sheep red blood cells in PBS (1% v/v, Torlak, Belgrade, 
Serbia) were treated for 1 h with concentration of compounds 
that corresponded to determined MIC and IC50 values at 37°C.  
Hemoglobin absorbance was measured at 405 nm (Tekan Infinite 
200 Pro multiplate reader (Tecan Group Ltd., Männedorf, 
Switzerland).  The hemolysis percentage was calculated using the 
following equation: hemolysis (%) = 100[(Abs405nm (treated) - 
Abs405nm (non treated) / (Abs405nm (0.1% Triton X-100 lysed) - 
Abs405nm (non treated)]. 
2.8. Liposomes leakage assay 
Mixtures containing L-α-phosphatidylcholine (PC, from egg 
yolk) (Sigma Aldrich, Munich, Germany) and L-a-
phosphatidylserine (PS, from bovine brain) (Sigma Aldrich, 
Munich, Germany) (PC/PS=8:2), or PC, PS and ergosterol 
(E)(Sigma Aldrich, Munich, Germany) (PC/PS/E=11/4/5) were 
dissolved in chloroform and dried under a stream of argone 
followed by vacuum drying. Large unilamellar vesicles (LUVs) 
with a diameter of 0.4 mm containing 50 mM calcein (Molecular 
Probes, Invitrogen) were prepared using an extruder (Avestin 
Europe GmbH., Mannheim, Germany) according to Hope et al.
31
 
The non-encapsulated dye was removed from the liposome 
suspension by ultracentrifugation. The osmolarity of the solution 
(calcein and buffer) was measured with an Osmomat 030, 
Gonotec GmbH (Berlin, Germany). 
Liposome leakage assay was performed in 96-well plate with 
50 nmol LUV suspension added per well and calcein release was 
recorded by measuring the fluorescence at excitation and 
emission wavelengths of 485 and 518 nm, respectively at room 
temperature using Tekan Infinite 200 Pro multiplate reader 
(Tecan Group Ltd., Männedorf, Switzerland). The percentage of 
fluorescence Ft at time t is defined as:  
% Ft=(It-I0/If-I0)x100; 
where I0 was the initial fluorescence obtained after the dilution of 
the vesicles in the appropriate buffer, If was the total fluorescence 
observed after addition of Triton X-100, and It was the 
fluorescence at time t corrected for the dilution. 
2.9. In vitro DNA binding by gel electrophoresis assay 
Genomic DNA (gDNA) from C. albicans was purified with a 
DNeasy tissue kit (Qiagen, Hilden, Germany).  The quality and 
the concentration of DNA were estimated by measuring UV 
absorbance with a NanoVue Plus spectrophotometer (GE 
Healthcare, Freiburg, Germany). The ability of guanylhydrazones 
to bind gDNA from C. albicans was examined by using agarose 
gel electrophoresis.
32
 Briefly, gDNA (500 ng) was treated with 
the compounds (25 μg mL-1) in phosphate buffer (pH 7.4), and 
the contents were incubated for 12 h at 37 °C, then subjected to 
gel electrophoresis on 0.8% (w/v) agarose gel containing 0.1 
μg/mL
 
of ethidium bromide in TAE buffer (40 mM Tris acetate/1 
mM EDTA, pH 7.4) buffer at 60 V for 2 h.  Gels were visualized 
and analyzed using the Gel Doc EZ system (Bio-Rad, Life 
Sciences, Hercules, USA), equipped with the Image Lab™ 
Software. 
2.10. The effect of guanylhydrazones on C. albicans yeast to 
hyphe transition using Spider medium 
Morphological changes of C. albicans in the presence and 
absence of guanylhydrazones and voriconazole in subinhibitory 
concentrations (MIC70; 70% of MIC value determined for the 
planktonic growth) was observed upon C. albicans growth on 
Spider medium as previously described.
33 
2.11. The effect of guanylhydrazones on Candida biofilm 
formation and disruption 
The biofilm disruption ability of guanylhydrazones was tested 
by determining minimal biofilm eradication concentration 
(MBEC), defined as the lowest concentration of an antimicrobial 
agent required to completely eradicate biofilm. Candida biofilms 
were developed in flat bottom 96-well clear microtitre plates as 
described previously.
34 
Briefly, harvested from the overnight 
grown liquid C. albicans ATCC10231, C. krusei ATCC34135 
and C. parapsilosis CA27 cultures were washed twice and 
collected by centrifugation (3000 × g) in sterile PBS, 
resuspended in RPMI-1640 with 2% glucose and adjusted to cell 
density of 1 × 10
6
 cells mL
-1
 using Neubauer haemocytometer. 
Biofilms were formed by pipetting 100 μL of the prepared cell 
suspension into wells of a microtiter plate and incubated for 48 h 
at 37°C. The established biofilms were rinsed with PBS to 
remove non-adherent cells and subsequently treated with two-
fold serial dilutions of guanylhydrazones (concentration range 
1000-25 µg mL
-1
). The resultant biofilm biomass was quantified 
using the CV assay and was compared with untreated controls. 
The bioassay was performed in six replicates of each strain.  
To study the effect of selected guanylhydrazones (11 and 18) 
on C. albicans biofilm formation, overnight fungal culture grown 
in RPMI medium supplemented with 2 % glucose and 10 % FCS 
was diluted to optical density OD600 of 0.1 and the biofilms 
were grown on plastic cover slips in the presence of MIC of 
guanylhydrazones or DMSO. After 24 h growth at 37 °C, 
biofilms were washed with PBS, stained with 2.5 µM propidium 
iodide (PI, Sigma Aldrich) and 50 µg mL
-1
 Concanavaline A 
conjugated with Fluorescence isothiocyanate (FITC; Sigma 
Aldrich) in PBS, and observed by microscopy. 
To examine the biofilm disruption activity of the same 
compounds, 48 – 72 h pre-formed C. albicans biofilms were 
washed with PBS and then incubated with MIC of 11 and 18 or 
DMSO in RPMI for 24 h followed by DAPI, PI and 
Concanavaline A staining as above. Biofilms and cells were 
examined using fluorescence microscope (Olympus BX51, 
Applied Imaging Corp., San Jose, USA) at 20× magnification. 
2.12. Molecular docking studies 
Glide module incorporated in the Schrödinger Molecular 
Modeling Package (Maestro Version 10.1.013, free trial) was 
  
 
used for performing molecular docking studies. For estimating 
protein-ligand binding affinities Glide Extra-Precision (XP) 
scoring function was adopted in the presented study. In this 
scoring function force field-based parameters like solvation and 
repulsive interactions, lipophilic, hydrogen bonding interactions, 
metal-ligand interactions as well as contributions from coulombic 
and van der Waals interaction energies are incorporated in the 
empirical energy functions calculations. Up to this day there is no 
reported X-ray structure of sterol 14α-demethylase (CYP51) 
from C. albicans. For this reason homology model was used for 
docking study.
35
 The X-ray structure of human CYP51 (PDB 
code: 3JUV) was obtained from the RCSB Protein Data Bank 
(PDB), http://www.rcsb.org/pdb. Protein preparation wizard with 
the application of the OPLS-2005 force field was applied for 
preparing protein-inhibitor complexes. Hydrogen atoms were 
added to the structure corresponding to pH 7.0 with the 
consideration of the appropriate ionization states for both the 
acidic and basic amino acid residues and any crystallographic 
water, if present was eliminated. Further, prepared structure was 
subjected to energy minimization until the average root 
meansquare deviation (r.m.s.d.) reached 0.3 Ǻ. The 3D structures 
of the studied molecules were built in the Maestro Suite of the 
module and subsequently optimized using the LigPrep module in 
the Schrödinger Suite. Partial atomic charges were computed 
using the OPLS-2005 force-field and possible ionization states 
were generated at a pH of 7.0. The ligand structures thus obtained 
were further optimized by energy minimization using the LBFGS 
method until a gradient of 0.01 kcal mol
-1
Å
-1
 was achieved.  
Molinspiration tool (Molinspiration Cheminformatics-2013) 
was used for calculating physic-chemical properties of 
investigated guanylhydrazones. For calculating of logP fragment-
based contributions and correlation factors were used. 
2.13. Zebrafish embryotoxicity of selected guanylhydrazones 
The assessment of toxicity (lethality and teratogenicity) of 
selected guanylhydrazones (11, 14 and 18) and voriconazole on 
zebrafish embryos was performed following general rules of the 
OECD Guidelines for the Testing of Chemicals.
36
 All 
experiments involving zebrafish were performed in compliance 
with the European directive 86/609/EEC and the ethical 
guidelines of Guide for Care and Use of Laboratory Animals of 
Institute for Molecular Genetics and Genetic Engineering, 
University of Belgrade. 
Adult zebrafish (Danio rerio, wild type) were maintained in 
the fish medium (2 mM CaCl2, 0.5 mM MgSO4, 0.7 mM 
NaHCO3, 0.07 mM KCl) at 27 ± 1°C and 14 h light/10 h dark 
cycle, and regularly fed twice daily with commercially dry flake 
food supplemented with Artemia nauplii (TetraMin
TM
 flakes; 
Tetra Melle, Germany). Eggs at 6 hours post fertilization (hpf) 
were treated with five different concentrations (2.5, 5, 10, 25, and 
50 μg mL
-1
) and 0.15% DMSO as negative control. Embryos 
were then individually transferred into 24-well plates containing 
1000 μl test solution, 10 embryos per well, and incubated at 
28°C. Experiments were repeated three times, using 30 embryos 
per concentration.  
Apical endopoints (Table S1) for toxicity evaluation were 
recorded at 24, 48, 72, and 96 hpf using an inverted microscope 
(CKX41; Olympus, Tokyo, Japan. At 96 hpf, the embryos were 
anesthetized by addition of 0.1% (w/v) tricaine solution (Sigma-
Aldrich, St. Louis, MO), photographed and killed by freezing at 
−20°C for ≥ 24 h.  
 
 
Scheme 1 Synthesis of the target compounds 10-16. Conditions: (i) ArB(OH)2, Pd(OAc)2, PPh3, DME, Na2CO3 aq, EtOH, 90 
o
C; (ii) H2NNHC(NH)NH2
.
HCl, 
EtOH, HCl, 90 
o
C. 
Scheme 2 Synthesis of the target compounds 17 and 18. Conditions: (i) (a) ArB(OH)2, Pd(OAc)2, PPh3, DME, Na2CO3 aq, EtOH, 90 
o
C; (b) 
H2NNHC(NH)NH2
.
HCl, EtOH, HCl, 90 
o
C; (ii) (a) ArB(OH)2, Pd(OAc)2, PPh3, DME, Na2CO3 aq, 90 
o
C; (b) H2NNHC(NH)NH2
.
HCl, EtOH, HCl, 90 
o
C 
Scheme 3 Synthesis of the target compound 21. Conditions: (i) (a) ArB(OH)2, Pd(OAc)2, PPh3, DME, Na2CO3 aq, 80 
o
C, µW; (b) DIBAL, PhMe, 0 
o
C; (ii) 
H2NNHC(NH)NH2
.
HCl, EtOH, HCl, 90 
o
C 
  
 
3. Results and discussion 
3.1. Chemistry 
The synthesis of guanylhydrazone derivatives 10-16 was 
accomplished using a simple two-step procedure described in 
Scheme 1. The first step involved Suzuki cross-coupling reaction 
between commercially available thiophene 1 and furan 2 
derivatives and arylboronic acids.
27
 Subsequent condensation of 
aldehydes 3-9 with aminoguanidine hydrochloride afforded 
compounds 10-16 in moderate to excellent yields. 
Following the similar two-step procedure guanylhydrazone 
derivative 17 and bis-guanylhydrazone 18 were obtained 
(Scheme 2). 
Preparation of the bis-guanylhydrazone 21 was accomplished 
by reaction of dialdehyde
 
20
28
 with aminoguanidine 
hydrochloride (Scheme 3). 
3.2. Antifungal activity and cytotoxic properties of 
guanylhydrazones 
The aldehyde 3 and guanylhydrazones 10-18 and 21 were 
evaluated for their in vitro antifungal activity against Candida 
albicans ATCC10231, Candida albicans CA5, Candida krusei 
ATCC34135, Candida parapsilosis C27, Aspergillus fumigatus 
ATCC13073, Fusarium oxysporum AB18, Microsporum canis 
DMT2 and Trichophyton mentagrophytes DMT4, where 
voriconazole was used as reference drug. The antifungal activity 
on well characterized clinical isolates (C. albicans CA5, C. 
parapsilosis C27, F. oxysporum AB18, M. canis DMT2 and  
T. mentagrophytes DMT4) was carried out at National Reference 
Medical Mycology Laboratory, Institute of Microbiology and 
Immunology, Faculty of Medicine, University of Belgrade, 
Serbia. Clinical isolates (C. albicans CA5, C. parapsilosis C27 
and F. oxysporum AB18) exhibited increased resistance towards 
standard antifungal compounds, including resistance to 
voriconazole. The results of in vitro antifungal screening (MIC 
values: minimal inhibitory concentrations that causes fungicidal 
effect) and cytotoxicity (IC50 values) of the test compounds are 
given in Table 1. 
All synthesized guanylhydrazones showed considerable 
antifungal activity against type strains, as well as human clinical 
isolates (Table 1). Aldehyde 3 did not show significant antifungal 
activity with MIC values of 250 µg mL
-1
 and 125 µg mL
-1
 against 
A. fumigatus, which indicated that the guanylhydrazone group 
was essential for the antifungal activity of the tested compounds. 
Thiophene-based guanylhydrazone 10 showed higher inhibitory 
activity than corresponding furan analog 16 against all screened 
fungi, so all further examined derivatives contained thiophene 
substructure. 
Nine out of ten guanylhydrazones exhibited promising activity 
against C. albicans type strain with MICs ranging from 0.9 to 7.8 
µg mL
-1
, with derivative 11 containing methyl group in the para-
position of the phenyl ring being the most active one. It is 
noteworthy that seven out of ten derivatives showed excellent 
activity against voriconazole resistant C. albicans CA5 with 
MICs ranging from 0.25 to 3.9 µg mL
-1
. In the case of this 
clinical isolate, bis-guanylhydrazone 21 exhibited the best 
activity with MIC in submicromolar range (MIC = 0.25 µg mL
-1
). 
Additionally, desirable high selectivity towards C. albicans CA5 
strain in comparison to human lung fibroblasts (SI = 20) was 
observed for compound 21 (Table 1). Similarly, 20-fold ratio was 
observed for another bis-guanylhydrazone derivative 18 in the 
case of C. albicans CA5 strain, suggesting lower cytotoxicity of 
bis-derivatives. 
 
Table 1 Antifungal activity and cytotoxic properties of guanylhydrazones 10-21 in comparison to aldehyde 3 and 
voriconazole (VOR) 
Compd 
Minimal inhibitory concentrations (MICs, µg mL-1) 
Cytotox. 
(µg mL-1)a 
Candida 
albicans 
ATCC10231 
Candida 
albicans 
CA5 
Candida krusei 
ATCC34135 
Candida 
parapsilosis 
C27 
Aspergillus 
fumigatus 
ATCC 13073 
Fusarium 
oxysporum 
AB18 
Microsporum 
canis 
DMT2 
Trichophyton 
mentagrophytes 
DMT4 
MRC5
b
 
3 250 250 >250 >250 125 250 250 250 50 
10 1.95 1.95 6.25 6.25 25 62.5 1.56 3.12 5 
11 0.90 0.50 3.12 3.90 6.25 7.8 1.56 1.56 2.5 
12 7.80 3.9 6.25 6.25 25 >250 0.97 3.12 5 
13 3.90 1.95 6.25 6.25 25 >250 0.97 1.56 4 
14 3.12 1.56 1.56 3.90 6.25 3.9 0.25 0.97 2 
15 3.90 7.80 25 12.5 25 >250 0.97 6.25 5 
16 7.80 15.6 50 50 125 125 1.56 6.25 20 
17 15.6 125 >250 >250 250 >250 125 25 25 
18 3.90 0.50 25 50 25 >250 0.97 3.90 10  
21 3.90 0.25 50 50 25 >250 0.25 0.25 5 
VOR
c
 0.50 R
d
 0.06 R 0.06 R 0.50 0.25 40 
a IC50; SD values ±2-5%. 
b human lung fibroblasts. c Control drug: VOR as a voriconazole. d Resistance. 
 
  
 
Guanylhydrazones 11 and 14 with methyl- and bromo-
substituent in para-position on the phenyl ring, respectively, 
showed broad spectrum activity. Of particularly interest was their 
activity against voriconazole resistant C. parapsilosis C27 (MIC 
= 3.9 µg mL
-1
) and F. oxysporum AB18 (11: MIC = 7.8 µg mL
-1
; 
14: MIC = 3.9 µg mL
-1
) strains. However, they both exhibited 
potent in vitro antirpoliferative effect on human fibroblasts 
(Table 1). Nevertheless, in the case of 11, MIC concentrations 
were 5 and 2.7 times lower in comparison to IC50 value for C. 
albicans CA5 and ATCC10231 strains, respectively. With 
respect to dermatophyte M. canis, compounds 14 and 21 showed 
improved activity (MICs = 0.25 µg mL
-1
) in comparison to the 
standard drug voriconazole (MIC 0.5 = µg mL
-1
). The MIC 
values for novel guanylhydrazones were comparable or better to 
recently reported novel triazole derivatives containing the 1,2,3-
triazole group against Candida strains.
37
 
Antifungal activity of new guanylhydrazones 10-17 was not 
apparently dependent on the electronic effect of substituent on 
phenyl ring. However, based on the activity of the compounds 11 
and 14, hydrophobic effect could be important for the 
pronounced antifungal activity. Interestingly, although deemed 
essential for antifungal activity, an additional guanylhydrazone 
substructure did not have an additive effect on the antifungal 
activity of compound 18 in comparison to parent compound 10 
against most of the tested strains. On the other side, bis-
guanylhydrazone 18 was 4 times more potent than 10 against 
voriconazole resistant C. albicans CA5 human clinical isolate. 
Based on the obtained results, compounds 11, 14 and 18 were 
identified as promising candidates and were further evaluated. 
Antifungal properties and time-kill dependence of selected 
guanylhydrazones were examined and followed further using 
subinhibitory concentrations of 11, 14 and 18 and compared to 
activity of voriconazole (Fig. 2A). 
Figure 2. Antifungal effect of selected guanylhydrazones on C. albicans 
growth. A) Time-kill effect of subinhibitory concentrations of 11 (diamond), 
14 (circle), 18 (black square), and voriconazole (triangle) on C. albicans 
growth measured by optical density in comparison to DMSO treated contol 
(white square). Effect of MIC concentrations of 11 (C) and 18 (D) on culture 
of C. albicans (OD600=1) after 2 h in comparison to DMSO treated culture 
(B) revealed by fluorescent microscopy using Concavaline-FITC/PI/DAPI 
staining. 
Figure 3. A) Hemolytic effect of guanylhydrazones using MIC (black 
bars) and IC50 (light grey bars) concentrations. B) Release of calcein from 
PC/PS and PC/PS/E liposomes in the presence of selected guanylhydrazones 
and voriconazole (VOR) and nystatin (NYS) was monitored for 30 min at 518 
nm. C) In-vitro DNA interaction ability of guanylhydrazones with C.albicans 
DNA (M-molecular marker λ DNA/HinDIII digest; C-DMSO treatment). 
Within 12 h of incubation, voriconazole-treatred cells reached 
the growth of the control that was treated with DMSO, while 11 
and 14 treated cells reached 50% of the control growth. On the 
other side, compound 18 exhibited pronounced fungistatic effect 
even after 12 h, not allowing the growth of C. albicans culture.  
However, within 24 h all cultures reached the full growth (results 
not shown). It can be concluded, that under conditions tested, 11 
and 14 showed better fungistatic effect then voriconazole, but not 
as good as 18. Next, we examined the effect of 11 and 18 on C. 
albicans membranes by the combined concavaline/PI/DAPI cell 
staining assay. PI is membrane impermeable dye and binds to 
nucleic acid only in the dead cells yielding fluorescence in the 
red wavelength region.  DAPI easily passes the membrane and 
strongly binds to DNA of both living and dead cells (giving blue 
color). C. albicans was treated with 11 and 18 MIC 
concentrations for 2 h and showed that treatment with compound 
18 induced the membrane damage and the cell death in only 
about 20 % cells according to red PI staining (Fig. 2 D). The cell 
death was not observed in Candida sample treated with 11, as PI 
staining of these cells (Fig. 2C) was comparable to non-treated 
control (Fig. 2B). None of the treatments induced apoptosis, 
since the DAPI staining appeared light blue and homogenous in 
all samples indicating the absence of nuclei condensation (Fig. 
2C and D). 
We also studied the effect of compounds on the membrane 
integrity of sheep red blood cells (RBC) to determine their ability 
to cause hemolysis and to examine their effect on cell membrane 
(Fig. 3A). We have monitored the release of haemoglobin from 
RBCs treated with concentrations of compounds corresponding 
  
 
to the lowest MIC against fungal strains and IC50 values (Table 1) 
and showed that generated guanylhydrazones mostly did not 
exhibit membrane disturbances (up to 10% hemolysis), except 
for 17 and 18 at 25 µg mL
-1
 and 10 µg mL
-1
 respectively, causing 
about 20% hemolysis (Fig. 3A). 
Given that polyenes, such as clinically used nystatin, with 
known membrane disturbance mode of action,
38,39
 caused 35-
40% hemolysis at 40 µg mL
-1
 (results not shown) under same 
conditions, we concluded that membrane may not be the primary 
target of novel guanylhydrazones. In addition, the ability of 
selected guanylhydrazones (11, 14, 18 and 21) to disrupt 
unilamellar liposomes was assessed (Fig. 3B). Two type of 
liposomes were included in the leakage assay: ones containing L-
α-phosphatidylcholine and L- α -phosphatidylserine (PC:PS) and 
the ones mimicking fungal membrane consisting of L-α-
phosphatidylcholine, L- α -phosphatidylserine and ergosterol  
(PC:PS:E) in the ratio 11:4:5. At MIC concentrations, only 18 
induced 8% PC:PS liposome leakage in comparison to that of 12 
and 21 induced by voriconazole and nystatin, respectively. 
However, low leakage of liposomes containing ergosterol and 
mimicking fungal membrane of 7-12% was induced by all 
selected guanylhydrazones at MIC concentrations (Fig. 3B). 
Therefore, membrane disruption was excluded as primary mode 
of action of these compounds. 
We also examined in-vitro interaction of these molecules with 
C. albicans genomic DNA using gel electrophoresis assay after 
prolonged incubation (12 h) of compounds (25 µg/mL) with 
purified DNA. This study was prompted by ability of the 
guanylhydrazone groups to bind to DNA.
40
 The basicity of the 
guanylhydrazone groups open possibilities that this functionality 
bind to the phosphate groups of the DNA molecule. Furthermore, 
intercalating properties might be also envisaged due to possible 
near planar geometry of guanylhydrazone group and aromatic 
ring. 
Under tested conditions, all guanylhydrazones, apart from 
aldehyde 3, showed the excellent and comparable ability to 
competitively intercalate double stranded fungal genomic DNA, 
which resulted in the inability of ethidum bromide to intercalate 
and emit under UV exposure (Fig. 3C).  Ethidium bromide is one 
of the most sensitive fluorescence probes for DNA binding: 
intercalation of a substrate into DNA leads to a decrease in the 
fluorescence intensity of the ethidium bromide-DNA complex. 
Significant and comparable DNA interaction properties of all 
tested guanylhydrazones lead to the conclusion that this may be a 
primary cause of their observed cytotoxicity, as well as one of the 
possible mechanisms of antifungal action (Table 1).  
3.3. Activity of guanylhydrazones against Candida biofilms 
C. albicans can grow in three different morphologies: yeast, 
pseudohyphae and hyphae. In particular, the hyphal form plays 
an important role during infection process and virulence
41
 and it 
is as critical in biofilm formation. Biofilms represent complex 
community of microorganisms surrounded by extracellular 
polymeric matrix that are attached to a surface, such as plastics 
and catheters.
42,43
 Biofilms protect microorganisms from host 
human immune system and antimicrobial agents.
44 
 Candida spp. 
biofilms are difficult to eradicate because they are resistant to 
most antifungal drugs, including the azoles and amphotericin B, 
but are susceptible to the echinocandins.
45 
Therefore, we have 
examined the effect of guanylhydrazones on Candida yeast to 
hypae transition, and biofilm formation and dispersion. 
Compounds 10-13, 15, 17 and 18, as well as voriconazole at 
sub-MIC concentrations (70% of MIC value determined for the 
Figure 4. Effect of subinhibitory amounts (MIC70) of guanylhydrazones 
derivatives on C. albicans hyphal growth. 
planktonic growth; MIC70) showed complete inhibition of  
C. albicans filamentous growth on the hyphal inducing Spider 
medium (Fig. 4). Guanylhydrazone 16 almost completely 
inhibited the formation of hyphe, while aldehyde 3 and 
compound 14 showed the inhibition to lesser extent in 
comparison to DMSO control. On the other hand, 21 that showed 
excellent activity against C. albicans CA5, apparently induced 
higher level of hyphal formation in comparison to the control 
(Fig. 4). 
Combined results for compounds 11 and 18 supported further 
screening for their ability to inhibit C. albicans biofilm formation 
and to disrupt pre-formed mature biofilms. C. albicans was 
cultured in the absence or in the presence of MIC concentrations 
of compounds 11 and 18, and biofilms were allowed to form on 
plastic coverslips for 24 h. Fluorescence isothiocyanate 
conjugated Concanavalin A-FITC staining of Candida cells 
demonstrated that, comparing to non-treated control, both 
compounds completely prevented the hyphal growth which is an 
essential feature for biofilm formation (Fig. 5A). Observed result 
was in accordance to obtained effects on the Spider medium (Fig. 
4) and showed that both compounds have an outstanding 
antifungal properties in terms of preventing Candida biofilms 
formation. Obtained result is very important, having in mind that 
C. albicans usually very readily forms biofilms on indwelling 
medical devices and mucosal tissues, which then serve as 
infectious reservoir that is difficult to eradicate and influence 
drug response.
46
 
When mature Candida biofilms were pre-formed for 48 h and 
then exposed to MIC concentrations of the same compounds, 
Concanavalin A-FITC staining showed that 11 was more 
effective in biofilm disruption (Fig. 5B) versus 18. However, 
minimal biofilm eradication concentration (MBEC) determined  
  
 
 
Figure 5. Activity of 11 and 18 on C. albicans biofilms. A) inhibition of biofilms formation and B) disruption of preformed Candida biofilms (Scale bar=10 µm) 
 
 
Figure 6. Effects of 11, 14 and 18 on development of zebrafish embryos in comparison to Vor and DMSO treated control at 96 hpf. LC50 represent compound 
concentration estimated to cause lethal effect in 50% of embryos. This data is from three repeat experiments. 30 embryos were tested for each treatment. 
Developmental embryos’ malformation such as pericardial edema (arrowhead), unresorbed egg yolk (asterisk), lordosys (dashed arrow), tail tissue disintegration 
(arrow), small head (bracket) and reduced otoliths (boxed) are denoted. 
. 
against mature biofilms of three strains C. albicans ATCC10231, 
C. krusei ATCC34135 and C. parapsilosis CA27 were all much 
higher than MIC values and in the range above 125 µg mL
-1
 
(Table S2) suggesting that these compounds could not be used 
for efficient biofilm eradication. 
3.4. In-vivo embryotoxicity assessment 
The zebrafish allows high-quality in-vivo validation of drug 
leads early in drug discovery, well before clinical trials serving as 
a very useful bioassay platform for toxicology studies.
47 
Therefore, the effects of the most potent guanylhydrazones 11, 14 
and 18 and those of voriconazole on the development of Danio 
rerio embryos were examined at concentrations close to MIC and 
IC50 values determined in antifungal and cytotoxicity assessment 
(Table 1). Strikingly, 18 showed no lethal or adverse 
developmental effects up to 50 μg mL
-1
, while LC50 values of 11 
and 14 were comparable and 2.6- and 4.5-fold higher in 
comparison to that of Vor, respectively (Fig 6). None of tested 
guanylhydrazones, applied at concentration of 2.5 μg mL
-1
, 
showed lethal or adverse developmental effects on treated 
embryos until 96 hpf (Fig. 6). Survived embryos upon Vor 
treatment, found only at 2.5 and 5 µg mL
-1
, were reduced in 
growth and exhibited a serious skeletal deformities, whereas at 5 
µg mL-1 embryos suffered of cardiac dysfunctions such as 
  
 
pericardial edemas, low heart beating and impaired caudal 
circulation (Fig. 6). Embryos treated with compounds 11 and 14 
did not developed scoliosis like those upon Vor treatment, and 
suffered only of relatively small pericardial edemas (Fig. 6). At 
the highest concentration of 11 (10 µg mL
-1
) and 14 (25 µg mL
-1
) 
where alive embryos were still detected, some tissue 
disintegration in tail region was observed. At 5 and µg mL
-1 
of 
11, embryos were reduced in growth, had smaller head and 
otoliths reduced in size (Fig. 6). 
Embryotoxicity data showed that at tested concentrations 11, 
14 and 18 were less embryotoxic and teratogenic than 
voriconazole. To the best of our knowledge there are no studies 
that evaluated voriconazole in zebrafish embryos model, however 
toxic side effects of this triazole drug have been recently reported 
such as visual disturbances through inhibition of TRPM1 and 
TRPM3 cation channels or the effect on renal function.
48,49
 
3.5. Molecular docking and evaluation 
In order to further evaluate possible mode of antifungal action 
of studied compounds, we have decided to examine one of the 
most studied molecular targets of antifungal compounds, namely 
lanosterol 14α-demethylase (CYP51) from the ergosterol 
biosynthetic pathway, by in silico molecular docking. CYP51 is a 
member of the cytochrome P450 super family and is implicated 
in the biosynthesis of fungal ergosterol, by catalyzing the 
oxidative removal of the 14α-methyl group of lanosterol to give 
the ∆
14,15
- unsaturated key intermediates.
50 
 Given that up to date 
the crystal structure of CYP51 enzyme for Candida spp. has not 
been obtained we have used appropriate homology model for 
computation analysis. It is reported that typical CYP51 inhibitors 
fit in the putative active site of CYP51 by a combination of heme 
co-ordination, hydrogen bonding, π-π stacking and hydrophobic 
interactions.
51,52
 These interactions at the active site of CYP51, 
provide the basis for the design of novel and potential antifungal 
agents with a broad antifungal spectrum and possibly with less 
potential to develop drug resistance. On the another hand, most 
commonly used antifungal drugs show undesirable side effect by 
reacting with human cytochrome P450 super family enzymes.
53 
Therefore, we have carried out comparative binding study of 
synthesized guanylhydrazones with CYP51 and human 
cytochrome P450 to examine the possibility if synthesized 
guanylhydrazones have the minimal structural prerequisites to 
interact with these targets. 
The docking scores of all studied compounds were calculated 
and top four studied compounds for both investigated enzymes 
according to Docking Score are presented in Table 2. In the case 
of C. albicans CYP51, the highest interaction was calculated for 
bis-guanylhydrazone 18, followed by 16, 12 and 3. In the case of 
human CYP51, compound 18 still had the highest calculated 
score, followed by 16, 17, and 13. The analysis of the Glide 
docking scores showed that these compounds docked to the 
active site of the cytochrome P450 sterol 14α-demethylase, so the 
antifungal activity of studied compounds could be reflected by 
their interaction with the heme cofactor as well as amino acids in 
the CYP51 active site, where the guanylhydrazones side chain 
plays very important role (Fig. 7). 
Furthermore, the interaction of these compounds at the active 
site of CYP51 may also be influenced by the heterocyclic ring 
fused to the main scaffold along with the substituents borne by it. 
It has to be noted that in presented study the real interaction 
profile for the synthesized compounds discussed herein has not 
been establish experimentally. However, it is interesting to 
discuss the predicted interactions for the best docking poses, 
since two and three compounds, respectively to studied enzyme, 
showed better activity in comparison to that of voriconazole. 
Surprisingly, one of the most active compounds 11, did not rank 
amongst the first five in docking analysis while inactive aldehyde 
3 did (Table 2). 
Docking mode of the best compounds poses, according to 
docking score, in the active site of CACYP51 is presented in 
Figure 6. There are many amino acid residues in the active site of 
cytochrome P450 sterol 14α-demethylase that can participate in 
close van der Waals and coulombic interactions with the 
inhibitor, when bound to it. For this reason the active site of 
cytochrome P450 sterol 14α-demethylase can be considered as 
highly conserved. Another important interaction of ligand with 
enzyme active site is the formation of hydrogen bond with amino 
acids. The amino acid THR-311 is most prominently involved in 
the interaction in the case of most ligands. Comparison of 
docking scores and other studied functions presented at Table 2 
revealed that compound 18 (Fig. 7A) possibly has better affinity 
for CACYP51 in comparison to human enzyme. Overall, good 
correlation between docking scores and antifungal activity was 
observed (Table 1, Table 2). 
Beside bis-guanylhydrazone 18, guanylhydrazones 11 and 14 
also showed pronounced antifungal activity (Table 1) and it was 
important to examine these two molecules closer through 
molecular docking study. Both compounds 11 and 14 have 
comparable binding energy (-37.549 kcal mol
-1
 and -42.449 kcal  
Table 2. Molecular docking data 
Compd 
Docking 
Score 
Glide evdw 
(kcal mol
-1
) 
Glide ecoul 
(kcal mol
-1
) 
Glide Energy 
(kcal mol
-1
) 
Glide Emodel 
(kcal mol
-1
) 
Hbond 
(kcal mol
-1
) 
 
C. albicans CYP51 
18 -6.953 -46.632 -2.688 -49.32 -73.003 -1.765 
16 -5.958 -33.459 -5.388 -38.846 -47.43 -1.304 
12 -5.431 -30.357 -2.822 -33.179 -50.543 0 
3 -5.38 -23.664 -2.992 -26.656 -35.746 -0.7 
 
Human CYP51 
18 -6.44 -39.031 -17.407 -56.438 -92.105 -2.308 
16 -6.166 -36.826 -9.226 -46.052 -67.781 -1.87 
17 -6.076 -30.717 -15.666 -46.384 -63.977 -2.525 
13 -5.617 -33.981 -9.564 -43.545 63.41 -0.991 
 
  
 
. 
 
Figure 7. Docking mode of A) 18 (top panel) and B) 11 (left) and 14 (right) in the active site of CACYP51. 
 
 
mol
-1
, respectively) and glide emodel was similar between two of 
them (-47.964 kcal mol
-1
 and -55.012 kcal mol
-1
). These two 
parameters for aldehyde 3 were much lower (Table 2 and Table 
S3). Docking mode of compounds 11 and 14 inside the active site 
of CACYP51 revealed strong interactions with amino acids PRO-
375 and MET-508 (Fig. 7B), which could indicate their 
importance in enzyme inhibition and can be correlated with their 
experimentally establish activity. 
Docking studies of compounds 11 and 14 with human CYP51 
revealed that among all studied compounds they have the lowest 
energy interactions with enzyme represented as docking score (-
4.609 for compound 11 and -4.295 for compound 14), and low 
values of binding energy (-44.330 kcal mol
-1
 and -28.262 kcal 
mol
-1
, respectively; -48.185 kcal mol
-1
 and -45.407 kcal mol
-1
 for 
glide emodel, respectively; Table S3), suggesting lower affinity 
towards human CYP51. Nevertheless, calculated low affinity 
towards human cytochrome P450 was not mirrored in 
antiproliferative cytotoxic experiments (Table 1). Overall, in 
silico analysis and docking study using CYP51s supported the 
hypothesis that inhibition of CACYP51 could be one of the 
mechanisms of antifungal activity of guanylhydrazone 
compounds. However, discrepancies between experimentally 
obtained data and predicted parameters from in silico analysis 
indicate that other modes of action could also be involved. 
Many problems in the drug development are the result of 
pharmacokinetic disadvantages such as poor absorption, first pass 
effect, a high degree of binding to the protein, therefore, 
establishing druglikeness is still a very important step in the 
search for new potential drug candidates. Druglikeness allows the 
assessment of the pharmacokinetic profile of the tested molecules 
based on the prediction of their absorption and distribution.  
Based on Lipinski’s “Rule of five”, the critical limit for 
acceptable drug-likeness is that no more than one violation of the 
rule exists in molecule.
25,26 
Molinspiration tool (Molinspiration Cheminformatics-2013) 
was used for calculating physicochemical properties of 
investigated guanylhydrazones. For calculating of logP fragment-
based contributions and correlation factors were used. Calculated 
physicochemical properties of investigated compounds are shown 
in Table S4. Data indicate that all guanylhydrazones except 18 
and 21 do not violate the “Rule of five”. For all investigated 
compounds clogP are below 4 and therefore they have favourable 
physicochemical profiles for oral bioavailability. Topological 
polar surface area (TPSA) is a good descriptor for the drug 
transport properties, drug absorption, including intestinal 
absorption, bioavailability, Caco-2 permeability. TPSA can be 
defined as a sum of the surface areas occupied by the oxygen and 
nitrogen atoms and the hydrogen atoms attached to them and 
represent the hydrogen bonding capacity of the molecules. 
Molecules with TPSA < 140 Å
2
 have good intestinal absorption, 
while those with TPSA < 60 Å
2 
show good blood–brain barrier 
penetration. All investigated compounds except 18 and 21 
satisfied the criterion for good intestinal absorption (Table S4). 
The number of H-bond donors and acceptors can be used for 
establishing hydrogen bonding capacity of the investigated 
compounds. An important factor for oral bioavailability, as well 
as for the efficient bonding to receptors and channels, is the 
conformational flexibility of the molecules described by the 
number of rotatable bonds. Sufficient oral bioavailability is 
expected for molecules with 10 rotatable bonds or fewer. In all 
investigated compounds there is at least one rotatable bond, but 
no more than 8 (compound 21).  
Summarizing the physicochemical properties of investigated 
compounds, conclusion can be made that they all meet criteria for 
good solubility and permeability and can be considered as 
potential drug candidates. 
4. Conclusions 
A new therapeutic options and better understanding of their 
mechanisms of action is essential to improving the outcome of 
fungal infections. A novel thiophene-based guanylhydrazones 
(iminoguanidines) were obtained in high yields using a simple 
  
 
two-step procedure. In vitro antifungal activity assays showed 
their potent, antifungal effect against yeasts, molds and 
dermaptophytes, the most common human and animal clinical 
isolates. Compounds 11, 18 and 21 exhibited excellent activity 
against voriconazole resistant C. albicans CA5 with MIC <1 µg 
mL
-1
 having selectivity index in comparison to human fibroblasts 
from 5 to 20. Additionally, bis-guanylhydrazone 18 showed 
better embryotoxicity profile, as well as better fungistatic effect 
in comparison to clinically used voriconazole and very efficiently 
inhibited Candida biofilm formation. Interaction with genomic 
DNA of C. albicans in vitro, indicated a possible mechanism 
of their activity. From the hemolysis experiments cell membrane 
was excluded as the primary target of these compounds, whereas 
in silico analysis and docking study using CYP51s supported the 
hypothesis that inhibition of CACYP51 could be one, but not the 
only mechanism of antifungal activity. For all compounds it has 
been calculated to have satisfying pharmacokinetic profile based 
on Lipinski’s “rule of five”. This study provides strong evidence 
that selected guanylhydrazone derivatives are good structural 
platform for further derivatization and possible application in 
antifungal therapy. 
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